Landmarks in non-muscle-invasive bladder cancer

Nature Reviews Urology

Volumn 11, Issue 8, 2014, Pages 476-480

  Mertens, Laura S ^a   Neuzillet, Yann ^b   Horenblas, Simon ^a   Van Rhijn, Bas W G ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BCG VACCINE; EPIRUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOMYCIN; PROTEIN P53; ANTINEOPLASTIC AGENT;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER STAGING; CYSTOSCOPY; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; REVIEW; TRANSURETHRAL RESECTION; ADJUVANT CHEMOTHERAPY; CYSTECTOMY; HUMAN; MORTALITY; PROCEDURES; PROGNOSIS; TUMOR INVASION; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CYSTECTOMY; CYSTOSCOPY; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84905968141     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2014.130     Document Type: Review

References (70)

1. National Cancer Institute. Seer Stat Fact Sheets: Bladder Cancer [online], http://seer. cancer.gov/statfacts/html/urinb.html (2014).
2. Wu, X., Ros, M. M., Gu, J. & Kiemeney, L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int. 102, 1207-1215 (2008).
3. Zeegers, M. P., Tan, F. E., Dorant, E. & van Den Brandt, P. A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer 89, 630-639 (2000). (Pubitemid 30640110)
4. Kiemeney, L. A. et al. Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat. Genet. 40, 1307-1312 (2008).
5. García-Closas, M. et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analysis. Lancet 366, 649-659 (2005). (Pubitemid 41176017)
6. Nieder, A. M., Porter, M. P. & Soloway, M. S. Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study. J. Urol. 180, 2005-2009 (2008).
7. Botteman, M. F., Pashos, C. L., Redaelli, A., Laskin, B. & Hauser, R. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21, 1315-1330 (2003). (Pubitemid 38041357)
8. Kamat, A. M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, diagnosis, and molecular markers. Eur. Urol. 63, 4-15 (2012).
9. Kirkali, Z. et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66 (Suppl. 1), 4-34 (2005). (Pubitemid 43049607)
10. Guyon, F., Lancereaux, E. & Mehu, C. Annales Des Maladies Des Organes Genito-Urinaires [French] (Nabu Press, 1884).
11. Leger, P. Histoire de la cystectomie totale pour traiter les tumeurs de vessie [French] (Schering).
12. Jewett, H. J. Infiltrating carcinoma of the bladder; relation of potential curability to depth of infiltration. Trans. Am. Assoc. Genitourin. Surg. 37, 51-65 (1945).
13. th edn (Wiley-Blackwell, 2009).
14. Mostofi, F. K., Sobin, L. H. & Torloni, H. Histological typing of urinary bladder tumors. World Health Organization [online], http://libdoc.who. int/publications/1973/9241760109-text-eng.pdf (1973).
15. Sauter, G. et al. in WHO classification of classification of tumours of the urinary system and male genital organs (eds Eble, J. N., Sauter, G., Epstein, J. l. & Sesterhenn, I.) 29-34 (IARCC Press, 2004).
16. Montironi, R., Lopez-Beltran, A., Mazzucchelli, R. & Bostwick, D. G. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J. Clin. Pathol. 56, 91-95 (2003). (Pubitemid 36177249)
17. Pellucchi, F. et al. Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. J. Urol. 186, 2194-2199 (2011).
18. Chen, Z. et al. The 1973 WHO Classification is more suitable than the 2004 WHO Classification for predicting prognosis in non-muscle-invasive bladder cancer. PLoS ONE 7, e47199 (1973).
19. Hall, M. C. et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1 and Tis): 2007 update. J. Urol. 178, 2314-2330 (2007). (Pubitemid 350080987)
20. Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur. Urol. 64, 639-653 (2013).
21. van Rhijn, B. W. et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J. Clin. Oncol. 21, 1912-1921 (2003). (Pubitemid 46606378)
22. Sidransky, D. et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706-709 (1991). (Pubitemid 21916998)
23. Olumi, A. F. et al. Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res. 50, 7081-7083 (1990). (Pubitemid 20361117)
24. Shariat, S. F., Ashfaq, R., Sagalowsky, A. I. & Lotan, Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J. Urol. 177, 481-487 (2007). (Pubitemid 46054033)
25. Moonen, P. M., van Balken-Ory, B., Kiemeney, L. A., Schalken, J. A. & Witjes, J. A. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J. Urol. 177, 80-83 (2007). (Pubitemid 44879442)
26. Schmitz-Dräger, B. J., Goebell, P. J., Ebert, T. & Fradet, Y. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur. Urol. 38, 691-699 (2000).
27. Malats, N. et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol. 6, 678-686 (2005). (Pubitemid 41222758)
28. Knowles, M. A. Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? Carcinogenesis 27, 361-373 (2006). (Pubitemid 43372866)
29. Karam, J. A., Shariat, S. F., Hsieh, J. T. & Knowles, M. A. Genomics: a preview of genomic medicine. BJU Int. 102, 1221-1227 (2008).
30. Burger, M. et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol. 54, 835-843 (2008).
31. Hernández, S. et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J. Clin. Oncol. 24, 3664-3671 (2006). (Pubitemid 46630542)
32. Cappellen, D. et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat. Genet. 23, 18-20 (1999).
33. Léger, P. Antonin Jean Desormeaux [French]. Prog. Urol. 14, 1231-1238 (2004).
34. Herr, H. W. Max Nitze, the cystoscope and urology. J. Urol. 176, 1313-1316 (2006). (Pubitemid 44307241)
35. Nezhat, C. Nezhat's History of Endoscopy: A Historical Analysis of Endoscopy's Ascension Since Antiquity (Endo Press, 2011).
36. Natalin, R. A. & Landman, J. Where next for the endoscope? Nat. Rev. Urol. 6, 622-628 (2009).
37. Bryan, R. T., Billingham, L. J. & Wallace, D. M. Narrow-band imaging flexible cystoscopy in the detection of recurrent urothelial cancer of the bladder. BJU Int. 101, 702-705 (2008). (Pubitemid 351269998)
38. Tearney, G. J. et al. Optical biopsy in human urologic tissue using optical coherence tomography. J. Urol. 157, 1915-1919 (1997). (Pubitemid 27171810)
39. Sonn, G. A. et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J. Urol. 182, 1299-1305 (2009).
40. Herr, H. W. & Donat, S. M. Quality control in transurethral resection of bladder tumours. BJU Int. 102, 1242-1246 (2008).
41. Sedelaar, J. P. M. & Witjes, J. A. Technique of TUR of bladder tumours: value of repeat TUR and random biopsies. EAU-EBU Update Series 5, 139-144 (2007). (Pubitemid 46930853)
42. Iglesias, J. J. & Fiore, G. Iglesias resectoscope with simultaneous irrigation, suction and low intravesical pressure. Eur. Urol. 1, 251-254 (1975).
43. Gupta, N. P., Saini, A. K., Dogra, P. N., Seth, A. & Kumar, R. Bipolar energy for transurethral resection of bladder tumours at low-power settings: initial experience. BJU Int. 108, 553-556 (2011).
44. Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466-475 (2006). (Pubitemid 43259554)
45. Burger, M. et al. ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol. 63, 36-44 (2013).
46. Soloway, M. S. Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res. 37, 2918-2929 (1977). (Pubitemid 8160449)
47. Semple, J. E. Papillomata of bladder treated with podophyllin; preliminary report. Br. Med. J. 1, 1235-1237 (1948).
48. Bateman, J. C. Chemotherapy of solid tumors with triethylene thiophosphoramide. N. Engl. J. Med. 252, 879-887 (1955).
49. Jones, H. C. & Swinney, J. Thiotepa in the treatment of tumours of the bladder. Lancet 2, 615-618 (1961).
50. Shida, K. et al. Treatment of the bladder cancer with instillations of mitomycin C. Jap. J. Clin. Urol. 21, 1075 (1967).
51. Huland, H. & Otto, U. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. Eur. Urol. 9, 84-86 (1983). (Pubitemid 13112541)
52. Lamm, D. L. Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. North Am. 19, 573-580 (1992).
53. Pearl, R. A note on the association of diseases. Science 70, 191-192 (1929).
54. Zbar, B. & Rapp, H. J. Immunotherapy of guinea pig cancer with BCG. Cancer 34 (Suppl.), 1532-1540 (1974).
55. Bloomberg, S. D., Brosman, S. A., Hausman, M. S., Cohen, A. & Battenberg, J. D. The effects of BCG on the dog bladder. Invest. Urol. 12, 423-427 (1975).
56. Martinez-Piñeiro, J. A. & Muntañola, P. Nonspecific immunotherapy with BCG vaccine in bladder tumors: a preliminary report. Eur. Urol. 3, 11-22 (1977).
57. Witjes, J. A. & Hendricksen, K. Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results. Eur. Urol. 53, 45-52 (2008). (Pubitemid 350167566)
58. Herr, H. W. et al. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J. Clin. Oncol. 13, 1404-1408 (1995).
59. Malmström, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur. Urol. 56, 247-256 (2009).
60. Gudjónsson, S. et al. Should all patients with non-muscle-invasive bladder cancer receive early Intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur. Urol. 55, 773-780 (2009).
61. Sylvester, R. J., Oosterlinck, W. & van der Meijden, A. P. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinial trials. J. Urol. 171, 2186-2190 (2004). (Pubitemid 38625431)
62. Solsona, E. et al. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J. Urol. 161, 1120-1123 (1999). (Pubitemid 29426099)
63. Mertens, L. S., Meinhardt, W., Rier, W. B., Nooter, R. I. & Horenblas, S. Extravasation of intravesical chemotherapy for non-muscle invasive bladder cancer. Urol. Int. 89, 332-336 (2012).
64. Sylvester, R. J., Oosterlinck, W. & Witjes, J. A. The schedule and duration of intravesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systemic review of the published results of randomized clinical trials. Eur. Urol. 53, 709-719 (2008).
65. Hendricksen, K. et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. Eur. Urol. 53, 984-991 (2008).
66. Sylvester, R. J., van der Meijden, A. P., Witjes, J. A. & Kurth, K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J. Urol. 174, 86-91 (2005). (Pubitemid 40825679)
67. Lamm, D. L. et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163, 1124-1129 (2000). (Pubitemid 30169376)
68. Reichert, D. F. & Lamm, D. L. Long term protection in bladder cancer following intralesional immunotherapy. J. Urol. 132, 570-573 (1984). (Pubitemid 14026175)
69. Lamm, D. L. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J. Urol. 134, 40-47 (1985). (Pubitemid 15006784)
70. Herr, H. W. Is maintenance Bacillus Calmette-Guérin really necessary? Eur. Urol. 54, 971-973 (2008).